Telix Accelerates AI Development with Dedicaid Acquisition
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
In the deck
Earlier from Telix Pharmaceuticals
- Q1 2023 Business update to accompany quarterly results
- Appendix 4C and Activities Report - March 2023 Quarter
- Telix Preclinical Development of Radiolabelled Olaratumab
- Illuccix European Marketing Authorisation Application Update
- FDA approval of expanded indication of Illuccix in the US
Later from Telix Pharmaceuticals
- Presentation to Accompany AI Development Program Update
- ZIRCON Data Presented at AUA Confirms Efficacy in 2cm Masses
- Annual General Meeting - Chairman and CEO Addresses
- Annual General Meeting - Presentation
- Phase II study for indication expansion of TLX250-CDx doses
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals